Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Before the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

More than 39 million people around the world could die from antibiotic-resistant infections over the next 25 years, according to a study published in The Lancet.  The new study by the Global Research ...

Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...

The efficacy of rucaparib plus nivolumab was compared with rucaparib monotherapy as maintenance treatment for ovarian cancer.

Results presented at ESMO showed tumor response rates that matched the bar set by analysts for success. But they may not yet be enough to dispel doubts around TIGIT as a target.

In a rough day for PARP inhibitors in ovarian cancer, GSK’s Zejula didn’t deliver a life extension benefit in the final ...